Press Releases2017-09-13T20:17:34+00:00

Press Releases

Amgen/Novartis’ Aimovig Label Revision and Teva’s Ajovy Autoinjector Delay Clear the Way for Continued Growth of Eli Lilly’s Emgality in the US Migraine Prevention Market, According to Spherix Global Insights

Neurologists and migraine specialists believe that a potential dual acute and preventive migraine indication for Lundbeck’s eptinezumab and Biohaven’s rimegepant could be influential in differentiating the pipeline agents from Allergan’s atogepant and the currently marketed CGRP therapies  EXTON, Pa., December 18, 2019 ― Eli Lilly’s Emgality, the third anti-calcitonin gene-related peptide (CGRP) therapy to the US market for the preventive treatment of migraine, continues to make headway in its efforts to catch up with the class leader, Amgen/Novartis’ Aimovig. Fielded between November 7th and 23rd, data from 102 migraine specialists and neurologists surveyed as part of the ongoing quarterly [...]

December 18, 2019|

Promising Early Launch Metrics for AbbVie’s Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights

As IL-6 inhibitor use in second- or later-line biologic/JAK therapy in RA declines and TNF class share remains flat, the introduction and positive early readout of the third JAK to market bodes well for the JAK inhibitor class. EXTON, Pa., December 16, 2019 /PRNewswire/ — Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently switched from one biologic/JAK to another agent via the 2019 annual RealWorld Dynamix™: Biologic/JAK Switching in Rheumatoid Arthritis (US) service. The patient chart analysis revealed that TNF inhibitor cycling remains the most common switch pattern among RA patients, though has leveled off over the [...]

December 16, 2019|

Neurologists Anticipate Overall Expansion of the Fumarate Class Following the US Launch of Biogen’s Vumerity for Treatment in Multiple Sclerosis, According to Spherix Global Insights

While neurologists are eager to believe that Vumerity will provide a superior tolerability profile over Biogen’s own Tecfidera, increasing first-line use of Genzyme’s Aubagio, Novartis’ Mayzent, and Genentech’s Ocrevus could present additional competitive pressure in the crucial new start patient segment  EXTON, Pa., December 10, 2019 ― Biogen’s Vumerity (diroximel fumarate), a monomethyl fumarate prodrug, was approved by the FDA on October 30th for the treatment of relapsing forms of multiple sclerosis (MS). Fielded between November 1st and 18th, data from 99 neurologists surveyed for the Q4 wave of the ongoing quarterly report series included in Spherix’s RealTime Dynamix™: [...]

December 9, 2019|

Janssen’s INVOKANA (canagliflozin) Gets Boost Over Competitors with FDA Approval for Diabetic Kidney Disease and a Newly Minted Collaboration with Renal Giant, Vifor Pharma

According to Spherix Global Insights, the approval of INVOKANA was highly anticipated among nephrologists and may present a paradigm shift in the way patients with type 2 diabetes and chronic kidney disease (CKD) are treated in the futureEXTON, Pa., November 25, 2019 – It is well-documented that nearly half of patients with type 2 diabetes will eventually develop diabetic kidney disease (DKD), which is the most common cause of kidney failure in the United States.  INVOKANA, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is the first agent shown to slow the progression of DKD since the standard of care (angiotensin-converting enzyme [...]

November 25, 2019|

Opportunity for EMD Serono’s Mavenclad is Growing in the Relapsing-Remitting Multiple Sclerosis Segment of the Canada Market, Although Increasingly Deferred Treatment Algorithm Positioning Is a Threat That Could Benefit Roche’s Ocrevus and Novartis’ Gilenya

With neurologists eagerly waiting for approval of Mayzent and interest growing in ofatumumab, Novartis is seen as a highly credible company with the potential to offer a diverse multiple sclerosis portfolio, according to Spherix Global Insights EXTON, Pa., November 19, 2019 ― Once approved by Health Canada and accessible on provincial drug formularies, the Canadian multiple sclerosis (MS) market is primed for swift adoption and solid uptake of Novartis’ Mayzent, especially if granted a first-in-market unrestricted secondary progressive MS (SPMS) indication. Data from 50 neurologists surveyed in October for an ongoing twice-yearly report series included in Spherix’s RealTime Dynamix™: [...]

November 19, 2019|

Novartis’ Mayzent and EMD Serono’s Mavenclad Look to Dethrone Genentech’s Ocrevus in the Expanding Patient Segment of Active Secondary Progressive Multiple Sclerosis

Following the recent relapsing forms of MS indication revision by the FDA, the unmet need for not active SPMS therapy has been put into stark contrast to other subtypes, while skepticism remains regarding the potential for MedDay Pharmaceuticals’ Qizenday, AB Science’s masitinib, or MediciNova’s ibudilast to emerge as the first-to-market solution, according to Spherix Global Insights EXTON, Pa., November 14, 2019 ― Following the recent March approvals of Novartis’ Mayzent and EMD Serono’s Mavenclad, Genentech’s Ocrevus continues to dominate neurologists’ stated preference across the three segments of patients with progressive forms of multiple sclerosis (MS): active secondary progressive MS [...]

November 14, 2019|